Fig 3.

Hazard function plots illustrating the estimated rate of relapse-free survival events at each time of follow-up (rate per patient per year). (A) Triple-negative, (B) HR-positive/HER2-negative, (C) HER2-positive breast cancer treated with paclitaxel followed by fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and (D) HER2-positive breast cancer treated with HER2-targeted therapy (trastuzumab) and sequential paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide (H+T/FEC) chemotherapy. Response categories are shown as pathologic complete response (pCR) or residual cancer burden (RCB)-I (blue), RCB-II (gray), and RCB-III (red). Y-axes use different scales; therefore, a black bar at hazard rate 0.10 was placed for reference. HR, hormone receptors; HER2, human epidermal growth factor receptor 2.